Merrimack Pharmaceuticals Profile

9.08
USD 0.06  0.67%
54%
56%

Acquisition by John Dineen of 7000 shares of Merrimack Pharmaceuticals subject to Rule 16b-3

Merrimack Pharmaceuticals insider trading alert for grant of stock option (right to buy) by John Dineen, the corporate stakeholder, on June 15, 2018. This event was filed by Merrimack Pharmaceuticals with SEC on 2018-06-15. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Merrimack Pharmaceuticals Summary

Merrimack Pharmaceuticals (MACK) is traded on NASDAQ General Markets in USA. It is located in MASSACHUSETTS, U.S.A and employs 72 people. Merrimack Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Small-Cap' category with current market capitalization of 120.35 M. Merrimack Pharmaceuticals conducts business under Healthcare sector and is part of Pharmaceutical Products industry. This company has 13.34 M outstanding shares of which 1.65 M shares are now shorted by private and institutional investors with about 21.0 trading days to cover. Merrimack Pharmac currently holds about 76.27 M in cash with (153.12 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.72.
Check Merrimack Pharmaceuticals Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Odds Below 9.08HorizonTargetOdds Above 9.08
79.07%30 days 9.08 20.67%
Based on normal probability distribution, the odds of Merrimack Pharmaceuticals to move above current price in 30 days from now is about 20.67% (This Merrimack Pharmaceuticals probability density function shows the probability of Merrimack Pharmaceuticals Stock to fall within a particular range of prices over 30 days) .

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Fmr LlcCommon Shares1.6 M13 M
Blackrock IncCommon Shares805.3 K6.5 M
View Merrimack Pharmaceuticals Diagnostics

Selected Merrimack Pharmaceuticals Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Merrimack Pharmaceuticals Against Markets

Current Ratings

Merrimack Pharmaceuticals 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
5 
Chance of
Financial Distress (0 to 100%)
84 
Equity ratings for Merrimack Pharmaceuticals are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Merrimack Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on biomarker-defined cancers in the United States. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts. Merrimack Pharmaceuticals operates under Biotechnology classification in USA and traded on NASDAQ General Markets. It employs 72 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameMerrimack Pharmaceuticals
CEORobert MulroyView All
Thematic Classification
Currently Active Investing Idea
  Cancer Fighters
View All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock View All
RegionNorth America
LocationMASSACHUSETTS, U.S.A
Business AddressOne Kendall Square
Foreign Associate  India
ExchangeNASDAQ General Markets
CIK Number01274792.0
CUSIP590328100
SectorHealthcare
IndustryPharmaceutical Products
BenchmarkDOW
Websitewww.merrimack.com
Contact Number617 441 1000
CurrencyUSD - US Dollar

Recommendations

Merrimack Pharmaceuticals Analyst Recommendations
Target PriceAdvice# of Analysts
6.0Hold2Odds
Merrimack Pharmaceuticals current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Merrimack Pharmaceuticals Analyst Advice  

Earnings

Merrimack Pharmaceuticals Earnings Estimates
EPSEstimate Date
Quarterly Estimate-0.22March 1, 2017
Merrimack Pharmaceuticals normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  

Directors

Merrimack Pharmaceuticals Corporate Directors
George Demetri Director
Vivian Lee Director, MBA
James Quigley Director, Ph.D
Please see also Stocks Correlation. Please also try Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.